Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.

Frankenstein L, Katus HA, Grundtvig M, Hole T, de Blois J, Schellberg D, Atar D, Zugck C, Agewall S; Norwegian Heart Failure Registry steering committee..

Eur J Clin Pharmacol. 2013 Oct;69(10):1747-55. doi: 10.1007/s00228-013-1512-x.

PMID:
23743778
2.

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.

Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.

Am J Cardiovasc Drugs. 2010;10(1):55-63. doi: 10.2165/11319940-000000000-00000.

PMID:
20104935
3.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators..

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
4.

Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.

Lund LH, Svennblad B, Melhus H, Hallberg P, Dahlström U, Edner M.

Circ Heart Fail. 2013 Mar;6(2):174-83. doi: 10.1161/CIRCHEARTFAILURE.112.000115.

5.

[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].

Pölzl G, Gouya G, Hügel H, Frick M, Ulmer H, Pachinger O.

Wien Klin Wochenschr. 2002 Oct 31;114(19-20):833-9. German.

PMID:
12503474
6.

[The role of aldosterone-antagonists in the treatment of congestive heart failure].

Fügedi K.

Orv Hetil. 2005 Apr 3;146(14):645-8. Review. Hungarian.

PMID:
15889538
8.

[Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].

Fabbri G, Gorini M, Maggioni AP, Di Lenarda A; Area Scompenso ANMCO, Firenze..

G Ital Cardiol (Rome). 2007 Feb;8(2):102-6. Italian.

PMID:
17402354
9.

Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.

Savarese G, Edner M, Dahlström U, Perrone-Filardi P, Hage C, Cosentino F, Lund LH.

Int J Cardiol. 2015 Nov 15;199:415-23. doi: 10.1016/j.ijcard.2015.07.051.

PMID:
26247798
10.

Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.

Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ, Vincent J, Pocock S, Zannad F; EMPHASIS-HF Study Group..

Circ Heart Fail. 2013 Jul;6(4):711-8. doi: 10.1161/CIRCHEARTFAILURE.112.000173.

11.

[Aldosterone receptor blockade after acute myocardial infarction with heart failure].

Bauersachs J, Ertl G.

Med Klin (Munich). 2006 Jun 15;101(6):458-66. Review. German.

PMID:
16767569
12.

Association of blood pressure and its evolving changes with the survival of patients with heart failure.

Grigorian-Shamagian L, Gonzalez-JuAnatey JR, Vazquez R, Cinca J, Bayes-Genis A, Pascual D, Fernandez-Palomeque C, Bardaji A, Almendral J, Nieto V, Macaya C, Jimenez RP, de Luna AB; Muerte Subita En La Insuficiencia Cardiaca (MUSIC) Group..

J Card Fail. 2008 Sep;14(7):561-8. doi: 10.1016/j.cardfail.2008.03.006.

PMID:
18722321
13.

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.

J Card Fail. 2004 Aug;10(4):297-303.

PMID:
15309695
14.
15.

[Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].

Roik M, Starczewska MH, Stawicki S, Huczek Z, Kochanowski J, Oreziak A, Furmańczyk A, Opolski G.

Pol Arch Med Wewn. 2006 Apr;115(4):321-8. Polish.

PMID:
17078490
17.
18.

Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.

Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group..

Am Heart J. 2006 Jan;151(1):55-61.

PMID:
16368292
19.

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.

McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Piña IL, Soler-Soler J, Swedberg K.

Eur J Heart Fail. 2005 Aug;7(5):710-21.

20.

Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.

Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA.

Am J Cardiol. 2008 Jul 1;102(1):79-83. doi: 10.1016/j.amjcard.2008.02.102.

PMID:
18572040
Items per page

Supplemental Content

Support Center